Surfactants, Pulmonary

PreclinicalSmall molecule

Surfactants, Pulmonary is one of 4 small molecule programs targeting Laryngeal Mask Airway. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Laryngeal Mask AirwayCompleted

Laryngeal Mask AirwayPreclinical

Completed

Competition

Competitive Landscape

4 competitors in Laryngeal Mask Airway

#DrugCompanyPhaseTrials

Nimbex

AbbVie

Preclinical

1 2

Alfenta

Jazz Pharmaceuticals

Preclinical

1 3

Remimazolam TIVA

YYonsei University

Preclinical

1 4

Surfactants, Pulmonary

UUniversity of Minnesota

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Laryngeal Mask Airway1 trial

Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates

Completed·UUniversity of Minnesota·N/A·NCT01116921·103 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Surfactants, Pulmonary. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Surfactants, Pulmonary compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Surfactants, Pulmonary. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Minnesota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Minnesota

Surfactants, Pulmonary

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Laryngeal Mask Airway1 trial

References

Drug Info

Quick Facts

Related News